2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Wannan C, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker J, Bearden C, Billah T, Bouix S, Broome M, Buccilli K, Cadenhead K, Calkins M, Cannon T, Cecci G, Chen E, Cho K, Choi J, Clark S, Coleman M, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Dwyer D, Ebdrup B, Ellman L, Fusar-Poli P, Galindo L, Gaspar P, Gerber C, Glenthøj L, Glynn R, Harms M, Horton L, Kahn R, Kambeitz J, Kambeitz-Ilankovic L, Kane J, Kapur T, Keshavan M, Kim S, Koutsouleris N, Kubicki M, Kwon J, Langbein K, Lewandowski K, Light G, Mamah D, Marcy P, Mathalon D, McGorry P, Mittal V, Nordentoft M, Nunez A, Pasternak O, Pearlson G, Perez J, Perkins D, Powers A, Roalf D, Sabb F, Schiffman J, Shah J, Smesny S, Spark J, Stone W, Strauss G, Tamayo Z, Torous J, Upthegrove R, Vangel M, Verma S, Wang J, Rossum I, Wolf D, Wolff P, Wood S, Yung A, Agurto C, Alvarez-Jimenez M, Amminger P, Armando M, Asgari-Targhi A, Cahill J, Carrión R, Castro E, Cetin-Karayumak S, Chakravarty M, Cho Y, Cotter D, D’Alfonso S, Ennis M, Fadnavis S, Fonteneau C, Gao C, Gupta T, Gur R, Gur R, Hamilton H, Hoftman G, Jacobs G, Jarcho J, Ji J, Kohler C, Lalousis P, Lavoie S, Lepage M, Liebenthal E, Mervis J, Murty V, Nicholas S, Ning L, Penzel N, Poldrack R, Polosecki P, Pratt D, Rabin R, Eichi H, Rathi Y, Reichenberg A, Reinen J, Rogers J, Ruiz-Yu B, Scott I, Seitz-Holland J, Srihari V, Srivastava A, Thompson A, Turetsky B, Walsh B, Whitford T, Wigman J, Yao B, Yuen H, Ahmed U, Byun A, Chung Y, Do K, Hendricks L, Huynh K, Jeffries C, Lane E, Langholm C, Lin E, Mantua V, Santorelli G, Ruparel K, Zoupou E, Adasme T, Addamo L, Adery L, Ali M, Auther A, Aversa S, Baek S, Bates K, Bathery A, Bayer J, Beedham R, Bilgrami Z, Birch S, Bonoldi I, Borders O, Borgatti R, Brown L, Bruna A, Carrington H, Castillo-Passi R, Chen J, Cheng N, Ching A, Clifford C, Colton B, Contreras P, Corral S, Damiani S, Done M, Estradé A, Etuka B, Formica M, Furlan R, Geljic M, Germano C, Getachew R, Goncalves M, Haidar A, Hartmann J, Jo A, John O, Kerins S, Kerr M, Kesselring I, Kim H, Kim N, Kinney K, Krcmar M, Kotler E, Lafanechere M, Lee C, Llerena J, Markiewicz C, Matnejl P, Maturana A, Mavambu A, Mayol-Troncoso R, McDonnell A, McGowan A, McLaughlin D, McIlhenny R, McQueen B, Mebrahtu Y, Mensi M, Hui C, Suen Y, Wong S, Morrell N, Omar M, Partridge A, Phassouliotis C, Pichiecchio A, Politi P, Porter C, Provenzani U, Prunier N, Raj J, Ray S, Rayner V, Reyes M, Reynolds K, Rush S, Salinas C, Shetty J, Snowball C, Tod S, Turra-Fariña G, Valle D, Veale S, Whitson S, Wickham A, Youn S, Zamorano F, Zavaglia E, Zinberg J, Woods S, Shenton M. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin 2024, 50: 496-512. PMID: 38451304, PMCID: PMC11059785, DOI: 10.1093/schbul/sbae011.Peer-Reviewed Original ResearchClinical high-risk individualsClinical high riskNational Institute of Mental HealthInstitute of Mental HealthAttenuated positive symptomsPersistent negative symptomsTransition to psychosisCHR statusHigh riskNegative symptomsPositive symptomsAnxiety symptomsPsychosocial functioningCognitive dataOutcomes of individualsDigital health technologiesDaily surveysPsychosisSCZPublic health needsMental healthNovel pharmacological interventionsSchizophreniaClinical outcomesHealth needs
2023
Sampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis
Hagler M, Ferrara M, Yoviene Sykes L, Li F, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Perkins D, Mathalon D, Seidman L, Tsuang M, Walker E, Powers A, Allen A, Srihari V, Woods S. Sampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis. Schizophrenia Research 2023, 255: 239-245. PMID: 37028205, PMCID: PMC10207144, DOI: 10.1016/j.schres.2023.03.047.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis servicesClinical high riskClinical high-risk individualsEarly detectionFirst-episode psychosis individualsRecent psychiatric hospitalizationCourse of illnessHigh-risk individualsAttenuated positive symptomsCHR researchGeographic catchmentSyndromal psychosisPsychosis individualsPsychiatric hospitalizationEarly intervention effortsHigh riskPsychosis servicesPositive symptomsGlobal functioningClinical resourcesProtective factorsDifferent populationsFE participantsGeneralizability of findingsFES programSelf-reported Gesture Interpretation and Performance Deficits in Individuals at Clinical High Risk for Psychosis
Karp E, Williams T, Ellman L, Strauss G, Walker E, Corlett P, Woods S, Powers A, Gold J, Schiffman J, Waltz J, Silverstein S, Mittal V. Self-reported Gesture Interpretation and Performance Deficits in Individuals at Clinical High Risk for Psychosis. Schizophrenia Bulletin 2023, 49: 746-755. PMID: 36939086, PMCID: PMC10154698, DOI: 10.1093/schbul/sbac197.Peer-Reviewed Original ResearchConceptsClinical high riskGesture deficitsInternalizing disordersCHR groupGesture interpretationLower verbal learningViable assessment toolVerbal learningNeurocognitive tasksGeneral intelligencePerformance deficitsNonverbal behaviorProcessing speedCHR participantsSimilar deficitsGreater deficitsHigh riskClinical InterviewFull psychotic disorderDeficitsSpecific subdomainsSRGPPsychotic disordersPsychosisGesturesComparing a Computerized Digit Symbol Test to a Pen-and-Paper Classic
Pratt D, Luther L, Kinney K, Osborne K, Corlett P, Powers A, Woods S, Gold J, Schiffman J, Ellman L, Strauss G, Walker E, Zinbarg R, Waltz J, Silverstein S, Mittal V. Comparing a Computerized Digit Symbol Test to a Pen-and-Paper Classic. Schizophrenia Bulletin Open 2023, 4: sgad027. PMID: 37868160, PMCID: PMC10590153, DOI: 10.1093/schizbullopen/sgad027.Peer-Reviewed Original ResearchClinical high riskCHR individualsFinger-tapping taskMotor ability measuresDigit symbol testCHR stateHealthy controlsHigh riskClinical InterviewPersistent subgroupSymbol testPersistent groupImpairmentPaper versionMotor abilitiesTask performance differencesComputerized versionSimilar degreeEffect sizeMeasures impairmentPsychosisCoding TestRemote assessmentSubgroupsDigit-symbol task
2022
Three prominent self-report risk measures show unique and overlapping utility in characterizing those at clinical high-risk for psychosis
Williams TF, Powers AR, Ellman LM, Corlett PR, Strauss GP, Schiffman J, Waltz JA, Silverstein SM, Woods SW, Walker EF, Gold JM, Mittal VA. Three prominent self-report risk measures show unique and overlapping utility in characterizing those at clinical high-risk for psychosis. Schizophrenia Research 2022, 244: 58-65. PMID: 35597134, PMCID: PMC9829103, DOI: 10.1016/j.schres.2022.05.006.Peer-Reviewed Original ResearchConceptsProdromal Questionnaire-BriefPositive symptomsSelf-report questionnairesSpecific positive symptomsStructured Clinical InterviewClinical high riskCriterion validityHealthy controlsSpecific symptomsHigh riskDiscriminant validityPsychosis symptomsClinical InterviewCHR individualsStrong convergent validitySymptomsPsychosis riskNeuropsychological testsConsistent significant correlationLimited specificitySignificant correlationConvergent validityPsychosisConstruct validityQuestionnaire
2021
Increased face detection responses on the mooney faces test in people at clinical high risk for psychosis
Silverstein SM, Thompson JL, Gold JM, Schiffman J, Waltz JA, Williams TF, Zinbarg RE, Mittal VA, Ellman LM, Strauss GP, Walker EF, Woods SW, Levin JA, Kafadar E, Kenney J, Smith D, Powers AR, Corlett PR. Increased face detection responses on the mooney faces test in people at clinical high risk for psychosis. Schizophrenia 2021, 7: 26. PMID: 34001909, PMCID: PMC8129098, DOI: 10.1038/s41537-021-00156-1.Peer-Reviewed Original ResearchClinical high riskFace perceptionCHR groupDegraded face imagesCognitive processesPerceptual sensitivityRisk mental stateMotivational mechanismsVisual perceptionFace testPerceptual abnormalitiesMental statesCHR participantsCHR subjectsMore facePerceptionDetection responseFace imagesYoung peoplePsychosisClinical measuresParticipantsPrior workFacePrior studiesComputerized Assessment of Psychosis Risk †
Mittal VA, Ellman LM, Strauss GP, Walker EF, Corlett PR, Schiffman J, Woods SW, Powers AR, Silverstein SM, Waltz JA, Zinbarg R, Chen S, Williams T, Kenney J, Gold JM. Computerized Assessment of Psychosis Risk †. Journal Of Psychiatry And Brain Science 2021, 6: e210011. PMID: 34307899, PMCID: PMC8302046, DOI: 10.20900/jpbs.20210011.Peer-Reviewed Original ResearchClinical high riskComputerized assessmentPsychosis riskPsychosis risk calculatorHelp-seeking individualsBehavioral tasksComputational mechanismsNeurobiological systemsCHR participantsCHR groupCHR researchGroup differencesIllness mechanismsClinical InterviewCutting-edge computational methodsOutcomes two yearsHealthy controlsYoung peoplePrevention effortsMinimal trainingPsychosisTrainingRisk individualsLearning methodsIndividuals
2020
Enhancing Psychosis Risk Prediction Through Computational Cognitive Neuroscience
Gold JM, Corlett PR, Strauss GP, Schiffman J, Ellman LM, Walker EF, Powers AR, Woods SW, Waltz JA, Silverstein SM, Mittal VA. Enhancing Psychosis Risk Prediction Through Computational Cognitive Neuroscience. Schizophrenia Bulletin 2020, 46: 1346-1352. PMID: 32648913, PMCID: PMC7707066, DOI: 10.1093/schbul/sbaa091.Peer-Reviewed Original ResearchConceptsClinical high riskComputational cognitive neuroscienceNew behavioral measureCognitive neuroscienceBehavioral measuresPsychosis risk predictionCognitive mechanismsTrait vulnerabilityDisorganization symptomsNeural systemsPsychosis symptomsPsychosis riskSpecialized interviewsPhenotype measuresNeuroscienceCHR assessmentTreatment targetsPsychotic disordersCourse of illnessInterview methodPsychosisNew treatment targetsIllness progressionPositive predictive valueMeasuresModeling perception and behavior in individuals at clinical high risk for psychosis: Support for the predictive processing framework
Kafadar E, Mittal VA, Strauss GP, Chapman HC, Ellman LM, Bansal S, Gold JM, Alderson-Day B, Evans S, Moffatt J, Silverstein SM, Walker EF, Woods SW, Corlett PR, Powers AR. Modeling perception and behavior in individuals at clinical high risk for psychosis: Support for the predictive processing framework. Schizophrenia Research 2020, 226: 167-175. PMID: 32593735, PMCID: PMC7774587, DOI: 10.1016/j.schres.2020.04.017.Peer-Reviewed Original ResearchConceptsClinical high riskCHR participantsDegraded speech stimuliPredictive processing frameworkUtility of interventionsSample of participantsPerceptual inferenceSensory evidencePsychotic spectrum disordersSpeech stimuliSpeech taskComputational underpinningsBehavioral tasksEfficacy of interventionsSpectrum disorderTarget tonesParticipants' performanceComputational modelingHigh riskPoor recognitionLatent factorsSuch tasksPrior beliefsTaskAppropriate risk stratification
2019
Predictive validity of conversion from the clinical high risk syndrome to frank psychosis
Yoviene Sykes LA, Ferrara M, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Perkins DO, Mathalon DH, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH, Woodberry KA, Powers AR, Ponce AN, Cahill JD, Pollard JM, Srihari VH, Woods SW. Predictive validity of conversion from the clinical high risk syndrome to frank psychosis. Schizophrenia Research 2019, 216: 184-191. PMID: 31864837, PMCID: PMC7239715, DOI: 10.1016/j.schres.2019.12.002.Peer-Reviewed Original ResearchConceptsFrank psychosisFirst-episode psychosis patientsOne-yearNorth American Prodromal Longitudinal StudySeverity of illnessClinical high-risk syndromeCurrent antipsychotic medicationsHigh-risk syndromePsychosis risk syndromeClinical high riskPredictive validityFEP casesPrescription ratesAntipsychotic medicationPsychosis patientsRisk syndromePsychosis onsetHigh riskLittle investigative attentionDiagnostic stabilityCHR individualsPsychosis paradigmPsychosisLongitudinal studySyndromeDoes hallucination perceptual modality impact psychosis risk?
Niles H, Walsh B, Woods S, Powers A. Does hallucination perceptual modality impact psychosis risk? Acta Psychiatrica Scandinavica 2019, 140: 360-370. PMID: 31355420, PMCID: PMC6752971, DOI: 10.1111/acps.13078.Peer-Reviewed Original ResearchConceptsClinical high riskPerceptual abnormalitiesPsychosis riskNon-verbal contentAuditory perceptual abnormalitiesIndividuals ages 12Verbal experienceAuditory experienceCHR individualsThought contentCHR sampleUnusual thought contentPredictive validityAuditory scoresGustatory componentsAge 12Meeting criteriaPsychotic disordersPhenomenological aspectsInterview notesPsychosisConversion riskScoresIndividualsExperience
2017
Lack of Diagnostic Pluripotentiality in Patients at Clinical High Risk for Psychosis: Specificity of Comorbidity Persistence and Search for Pluripotential Subgroups
Woods SW, Powers AR, Taylor JH, Davidson CA, Johannesen JK, Addington J, Perkins DO, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA, Seidman LJ, Tsuang MT, Walker EF, McGlashan TH. Lack of Diagnostic Pluripotentiality in Patients at Clinical High Risk for Psychosis: Specificity of Comorbidity Persistence and Search for Pluripotential Subgroups. Schizophrenia Bulletin 2017, 44: 254-263. PMID: 29036402, PMCID: PMC5814797, DOI: 10.1093/schbul/sbx138.Peer-Reviewed Original ResearchConceptsCHR syndromeDiagnostic outcomesCHR subgroupsClinical high-risk syndromeHigh-risk syndromeOnset of psychosisClinical high riskPersistence of anxietyEmergent psychosisCHR patientsRisk syndromeObservational studyCHR casesHigh riskNonpsychotic disordersComorbid disordersComparison subjectsBipolar disorderDiagnostic InterviewSyndromeDSM-IVPatientsPsychosisDiagnostic specificityComparison group